Dr John Haylor BPharm PhD MRPS

Senior Lecturer

Photograph of Dr John Haylor

Academic Unit of Nephrology
Department of Infection and Immunity
The University of Sheffield Medical School
Beech Hill Road
S10 2RX
United Kingdom

Tel: +44 (0)114 271 2563
Fax: +44 (0)114 271 3892
Email: j.l.haylor@sheffield.ac.uk
Secretary - Mrs Jean Lazenby
Tel: +44 (0)114 271 2237
Email: j.lazenby@sheffield.ac.uk


I originally trained as a pharmacist but have worked as both a physiologist and pharmacologist moving to Sheffield in 1980 to help establish a new dual honours degree in pharmacology and chemistry. Under the leadership of Dr Godfrey Collins, we developed a very successful undergraduate pharmacology course taught over a period of some 25 years.

In 1993, I moved to the Sheffield Kidney Institute at the Northern General Hospital to work with Professor Meguid El Nahas, to develop drug therapies to slow the progression of chronic kidney disease.  A strong research link was also established with Professor Sameh Morcos in Diagnostic Imaging to study the toxicity of radio/MRI contrast media.

In 2007, now as the Academic Nephrology Unit, we joined the Department of Infection and Immunity in the Medical School, in Sheffield.   I hold a Home Office Project Licence and am involved in collaborative projects to slow the progression of chronic kidney disease with both Professor ACM Ong (polycystic kidney disease) and Prof T Johnson (transglutaminase). 

I am interested in undergraduate medical education and have undertaken an MEd degree.

Research Interests

I have always worked on the kidney, initially in eicosanoid physiology/pathology, while collaborative projects in Diagnostic Imaging involved studies on the nephrotoxicity of iodine-based contrast agents and on the pathophysiology of nephrogenic systemic fibrosis (NSF) induced by gadolinium-based MRI agents. 

Six rodent models of chronic kidney disease (CKD) have been established and used to study new methods of slowing renal progression.  Initially involving the the GH-IGF1 pathway but including apoptotic (capase-3) and proliferative (MEK) pathways and the enzymatic control of matrix protein deposition (transglutaminase).  Additional techniques have involved an extensive use of the isolated kidney to study nitric oxide and endothelin autacoids and the development of rat models of chronic allograft nephropathy through kidney transplantation.  Major papers have been published on:

  • recombinant human IGF-I in the treatment of end stage renal disease .
  • endothelin antagonists the prevention of acute renal failure caused by radiocontrast media .
  • transglutaminase inhibitors in slowing the progression of hypertensive and diabetic kidney disease.

Teaching Interests

I lecture on renal physiology and on all aspects of pharmacology, including the autonomic nervous, central nervous, cardiovascular, endocrine, immune and gastro-intestinal systems.  Together with Dr Richard Marks we have developed a new pharmacology course for 2nd year medical students in Sheffield.  I am the Sheffield representative for the Prescribing Safety Assessment (PSA).

Professional Activities

I am a director of the Sheffield Kidney Research Foundation and was renal/endocrine editor for the British Journal of Pharmacology.  I am a grant reviewer for Kidney Research UK, manuscript referee for many kidney and pharmacology journals and external examiner for the medical course at Keele University.

Current projects

  • Antibody inhibitors of transglutaminase as potential anti-fibrotic agents in the kidney and lung in (collaboration with MRC technology, Dr Phil Watson and Professor Tim Johnson)
  • Kidney transplantation and renal transglutaminase.

Key Publications

        Latest 5

  1. Hornigold N, Johnson TS, Huang L, Haylor JL, Griffin M, Mooney A. Inhibition of collagen I accumulation reduces glomerulosclerosis by a Hic-5-dependent mechanism in experimental diabetic nephropathy. Lab Invest. 2013 May;93(5):553-65.
  2. Nutter F, Khwaja A, Haylor J.Seliciclib inhibits renal hypertrophy but not fibrosis in the rat following subtotal nephrectomy. Nephron Exp Nephrol. 2012;122(3-4):114-22.
  3. Vass DG, Shrestha B, Haylor J, Hughes J, Marson L. Inflammatory lymphangiogenesis in a rat transplant model of interstitial fibrosis and tubular atrophy. Transpl Int. 2012 Jul;25(7):792-800.
  4. Haylor J, Schroeder J, Wagner B, Nutter F, Jestin G, Idée JM, Morcos S. Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis. Radiology. 2012 Apr;263(1):107-16.
  5. Haylor JL, Harris KP, Nicholson ML, Waller HL, Huang Q, Yang B. Atorvastatin improving renal ischemia reperfusion injury via direct inhibition of active caspase-3 in rats. Exp Biol Med (Maywood). 2011 Jun 1;236(6):755-63.

    Some Key Older Publications

  6. Haylor J, Dencausse A, Vickers M, Nutter F, Jestin G, Slater D, Idee J-M, Morcos SK. Nephrogenic gadolinium biodistribution following a single injection of Omniscan in the rat. Invest Radiol 2010;45:507-512.
  7. Kuan Y, Surman J, Frystyk J, El Nahas AM, Flyvbjerg A, Haylor JL. Lack of effect of IGF-I on the glomerular filtration rate in non-diabetic patients with advanced chronic kidney disease. Growth Hormone and IGF Research 2009;19:219-225.
  8. Ahmed A, Huang L, Raftery AT, Ahmed AK, Fahmy H, El Nahas AM, Haylor JL. Cyclosporine A sensitizes the kidney to tubulointerstitial fibrosis induced by renal warm ischaemia. Transplantation 2004;77:686-692.
  9. Oldroyd SD, Haylor JL Morcos SK. Bosentan, an orally active endothelin receptor antagonist: Effect on the renal response to contrast media. Radiology 1995;196:661-665.
  10. Burton GA, MacNeil S, de Jonge A, Haylor J. Cyclic GMP release and vasodilatation induced by EDRF and atrial natriuretic factor in the isolated perfused kidney of the rat. Brit J Pharmacol 1990;99:364-368.

For PubMed Search click here